Centessa Pharmaceuticals plc

CNTASEC EDGAR

Pharmaceutical Preparations(X0)CIK: 1847903

Concept	FY2024	FY2023	FY2022	FY2021
Revenues	$6.9M	$0.00	—	—
Operating Income (Loss)	-$171.3M	-$212.3M	-$783.0K	-$5.1M
Interest Expense	—	$7.3M	—	—
Other Nonoperating Income (Expense)	-$5.4M	$2.3M	$0.00	$105.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$176.1M	-$217.0M	-$829.0K	-$5.1M
Income Tax Expense (Benefit)	-$25.1M	-$747.0K	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$151.1M	-$216.2M	-$829.0K	-$5.1M
Earnings Per Share, Basic	-$1.57	-$2.31	-$5.07	-$5.07
Earnings Per Share, Diluted	-$1.57	-$2.31

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$360.2M	$444.3M	$629.6M	$11.7M
Assets, Current	$315.1M	$437.7M	$628.8M	$11.2M
Cash and Cash Equivalents, at Carrying Value	$128.0M	$393.6M	$595.1M	$7.2M
Liabilities	$124.0M	$108.1M	$138.1M	$8.6M
Liabilities, Current	$39.4M	$38.3M	$24.6M	$8.6M
Long-term Debt	$0.00	—	—	—
Accounts Payable, Current	$11.8M	$13.8M	$8.1M	$1.0M
Stockholders' Equity Attributable to Parent	$336.2M	$491.6M	-$4.7M	$491.6M
Common Stock, Shares, Outstanding

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$160.3M	-$200.5M	-$1.0M	-$5.8M
Net Cash Provided by (Used in) Investing Activities	-$127.0M	-$931.0K	$0.00	$0.00
Net Cash Provided by (Used in) Financing Activities	$21.1M	$457.0K	$0.00	$9.0M
Payments to Acquire Property, Plant, and Equipment	$169.0K	$1.1M	$0.00	$0.00
Payments for Repurchase of Common Stock	—	—	—	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)